Business Standard

Bharat Biotech starts Covaxin's at-risk manufacturing; expanding capacity

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Premium

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Sohini Das Mumbai
As India’s first indigenous Covid-19 vaccine candidate gets the nod for phase 3 trials, Hyderabad-based vaccine maker Bharat Biotech has not only started the at-risk manufacturing of its candidate Covaxin, but is also looking to ramp up capacities.

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results. 

Besides setting up a second plant at its Genome Valley facility in Hyderabad to make Covaxin, the firm is looking for another site in the country to make the vaccine.

Speaking to Business Standard, Sai Prasad, executive director at Bharat Biotech International (BBIL), said: “We are

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in